Abstract 140P
Background
The high recurrence rate after surgical resection remains a big challenge for long-term survival of HCC patients. In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of perioperative treatment. This study aimed to evaluate the efficacy and safety of combining tislelizumab with Lenvatinib and TACE as neoadjuvant therapy in resectable CNLC IIa-IIb HCC patients.
Methods
This study (ClinicalTrials.gov NCT06003673) enrolled patients with primary resectable HCC of CNLC IIa-IIb who had not received prior systemic therapy. For CNLC IIa patients must meet one of the following criteria: unclear tumor boundaries, proximity to blood vessels, or suspicious residual margins. TACE will be performed once only on Day 1. Tislelizumab (200 mg, IV, Q3W) and lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily was initiated on Day1. All patients undergo 2 cycles of neoadjuvant therapy. Patients will undergo surgical resection within 2-4 weeks after neoadjuvant treatment depends on the investigators’ evaluation. Primary endpoint was relapse-free survival (RFS). Secondary endpoints were objective response rate (ORR) by RECIST v1.1, Pathological Complete Response Rate (pCR), Major pathological reactions (MPR), R0 resection rates, overall survival (OS), and adverse events (AE).
Results
Between July 2023 and August 2024, 23 patients were enrolled. As of September 29, 2024, after a median follow-up of 9.4 months. All patients received neoadjuvant, and 19 patients underwent successful R0 resection, 7 patients (7/19,36.9%) achieved complete pathological response, 10 patients (10/19, 52.6%) achieved major pathological reaction (necrosis > 90%). The median age was 59 years old,all Child-Pugh A(100%), ECOG PS 0(100%), mostly males (82.6%), HBV infection (76.2%), BCLC B(100%) and CNLC IIa (63.6%). No grade 4 or 5 TRAE were observed. Median RFS and overall survival were not reached.
Conclusions
Lenvatinib, tislelizumab, and TACE were safe and showed promising efficacy as a neoadjuvant therapy for resectable HCC of CNLC IIa-IIb . Further follow up will continue.
Clinical trial identification
NCT06003673.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract